Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income (2016 - 2025)

Agios Pharmaceuticals' Net Income history spans 13 years, with the latest figure at -$108.0 million for Q4 2025.

  • For Q4 2025, Net Income fell 11.93% year-over-year to -$108.0 million; the TTM value through Dec 2025 reached -$414.6 million, down 161.83%, while the annual FY2025 figure was -$412.8 million, 161.27% down from the prior year.
  • Net Income reached -$108.0 million in Q4 2025 per AGIO's latest filing, down from -$103.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $2.0 billion in Q1 2021 to a low of -$112.5 million in Q2 2025.
  • Average Net Income over 4 years is $116.4 million, with a median of -$88.0 million recorded in 2023.
  • Peak YoY movement for Net Income: surged 4382.87% in 2021, then tumbled 110.91% in 2025.
  • A 4-year view of Net Income shows it stood at $4.0 million in 2021, then tumbled by 2524.56% to -$95.9 million in 2023, then fell by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Net Income are -$108.0 million (Q4 2025), -$103.4 million (Q3 2025), and -$112.5 million (Q2 2025).